Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PCSA 
Processa Pharmaceuticals Inc (PCSA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: PCSA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1
1 Year Target Price $1
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -64.09% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.55M USD | Price to earnings Ratio - | 1Y Target Price 1 |
Price to earnings Ratio - | 1Y Target Price 1 | ||
Volume (30-day avg) 1 | Beta 1.35 | 52 Weeks Range 0.15 - 1.50 | Updated Date 09/14/2025 |
52 Weeks Range 0.15 - 1.50 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.31 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -102.62% | Return on Equity (TTM) -212.38% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2635162 | Price to Sales(TTM) - |
Enterprise Value 2635162 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.14 | Shares Outstanding 50349100 | Shares Floating 42546038 |
Shares Outstanding 50349100 | Shares Floating 42546038 | ||
Percent Insiders 12.08 | Percent Institutions 5.99 |
Upturn AI SWOT
Processa Pharmaceuticals Inc
Company Overview
History and Background
Processa Pharmaceuticals, Inc. was founded in 2007. It is a clinical-stage biopharmaceutical company focused on developing next generation chemotherapeutics to improve the survival and quality of life for cancer patients.
Core Business Areas
- Oncology Drug Development: Focused on developing drugs for cancer patients who have not responded adequately to existing therapies, including proprietary drug candidate PCS499 for advanced gastrointestinal cancer.
Leadership and Structure
Dr. David Young is the CEO. The company has a board of directors and a management team focused on clinical development and commercialization.
Top Products and Market Share
Key Offerings
- PCS499: A proprietary drug candidate in clinical development for advanced gastrointestinal cancer. Market share is currently 0% as it is in clinical trials. Competitors include existing chemotherapy drugs and other investigational therapies in development for similar indications. Potential competitors: Bristol Myers Squibb (BMY), Merck (MRK), Roche (ROG.SW), Amgen (AMGN)
- Next Generation Chemotherapeutics: Focused on developing drug candidates that can improve the survival and quality of life for cancer patients.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and constantly evolving, with a focus on developing new and improved treatments for diseases, including cancer. Trends include personalized medicine, gene therapy, and immunotherapy.
Positioning
Processa Pharmaceuticals is positioned as a developer of next-generation chemotherapeutics targeting unmet needs in cancer treatment. Their competitive advantage lies in their specific focus on therapies that are intended to improve the survival and quality of life for cancer patients.
Total Addressable Market (TAM)
The global oncology market is estimated to be worth hundreds of billions of dollars. Processa is positioned within a niche market, focusing on gastrointestinal cancers and therapies that overcome resistance, thus capturing a portion of this large TAM. Exact TAM for PCS499 is dependent on successful trial outcomes and market penetration.
Upturn SWOT Analysis
Strengths
- Proprietary drug candidate (PCS499)
- Experienced management team
- Focus on unmet medical needs
- Next generation chemotherapeutics.
Weaknesses
- Limited financial resources
- Dependence on clinical trial outcomes
- Early-stage development risk
- No products currently generating revenue
Opportunities
- Successful clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Regulatory approvals and market access
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Economic downturn impacting funding
Competitors and Market Share
Key Competitors
- BMY
- MRK
- ROG.SW
- AMGN
Competitive Landscape
Processa faces significant competition from established pharmaceutical companies with greater resources and more advanced pipelines. Its competitive advantage lies in focusing on specific unmet medical needs and developing novel therapeutic approaches.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by preclinical and clinical development activities rather than revenue growth.
Future Projections: Future growth is dependent on the successful development and commercialization of PCS499 and other drug candidates.
Recent Initiatives: Ongoing clinical trials for PCS499 and exploration of additional indications, partnerships with academic institutions and CROs.
Summary
Processa Pharmaceuticals is a high-risk, high-reward clinical-stage company focused on developing next-generation chemotherapeutics. Its success hinges on positive clinical trial outcomes for PCS499 and other drug candidates. The company's financial stability depends on continued funding, and it faces stiff competition from larger, more established pharmaceutical companies. Investors should closely monitor clinical trial progress and regulatory milestones.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on publicly available information and may not be complete or accurate. Investment decisions should be made based on individual due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Processa Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Hanover, MD, United States | ||
IPO Launch date 2017-10-10 | CEO & Director Mr. George K. Ng Esq., J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 10 | |
Full time employees 10 | |||
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine, which is in Phase 2 clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 that is in Phase 2B clinical trials for treatment of gastroparesis; and PCS499 for the treatment of glomerular disease. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2017 and is based in Hanover, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.